PaceMate Hits 100,000th Patient Transmission Milestone with Cutting-Edge Ambulatory Remote Monitoring Platform

Significant Achievement Cements the Company’s Leadership in Cardiac Data Management

SARASOTA, Fla.–(BUSINESS WIRE)–PaceMate®, a market-leading cardiac remote monitoring and cardiac data management platform, announced today the completion of its 100,000th ambulatory patient transmission managed through PaceMateLIVE™. This achievement shows PaceMate as a proven solution with tangible results in real-world applications.

PaceMate leverages advanced algorithms to deliver the only end-to-end solution, merging the entire workflow – from ordering to billing – into a singular, efficient experience. PaceMate automates device ordering, calculates wear time, and automatically scripts reports, minimizing denials and ensuring accurate billing information is processed. With PaceMate, clinicians experience a 50% reduction in time spent on administrative ambulatory-related tasks, transforming more than 150-clicks into a concise 3-click process.*

“This milestone is not just a number – it’s a testament to the trust and reliance placed in us by healthcare providers and their patients across the nation. PaceMate is the universal solution for cardiac data management across the disease spectrum,” said Tripp Higgins, CEO and Co-Founder of PaceMate. “We are proud to offer the only platform that integrates with all major ambulatory patch vendors, granting healthcare providers the freedom to choose and ensuring the best care for their patients,” said Higgins.

PaceMate provides clinicians the flexibility to choose from the top five ambulatory monitoring manufacturers with one single integration for a tailored healthcare solution.

“One of the most valuable aspects of PaceMate is the flexibility it offers in selecting ambulatory vendors that best fit our specific needs, thanks to its comprehensive integrations with all major ambulatory patch vendors,” said Saumil Oza, M.D., FACC, Ascension Medical Group, St. Vincent’s. “This flexibility gives us significant choice and contracting power, which is a critical advantage. PaceMate’s capability to integrate wearable technologies has transformed our operational efficiency, eliminating the need to navigate between multiple platforms. This has been a game-changer for our practice and significantly enhanced patient care.”

This milestone comes after strategic investment by Lead Edge Capital, a growth stage investment firm focused on the internet, software, consumer, and tech-enabled service sectors. PaceMate remains steadfast in its commitment to improving lives and continues to push the boundaries in healthcare technology, making significant strides in cardiac care.

About PaceMate:

PaceMate is a pioneering force in remote cardiac data management. We’re driven by a mission to modernize digital healthcare and envision a future of connected personalized cardiac care. Since 2015, PaceMate has been simplifying and streamlining device clinic operations into one easy-to-use platform. PaceMateLIVE offers the most comprehensive remote cardiac monitoring solution, uniquely pairing device and EHR data to easily prioritize patient care intelligently. Join us at PaceMate.com to see how together, we never miss a beat.

*Warren, Jaime Ed.D, MBA, BHS, CNMT, NCT, FACC, Kennedy, Jenny, MSN, RN, CHFN, NEA-BC, “Streamlining Ambulatory Cardiac Monitoring: A Case Study on PaceMate Remote Monitoring”; MedAxiom, March 2024.

Contacts

Haley Chute

haley.chute@pacemate.com

Staff

Recent Posts

Health Care AI Initiative Launched by Paragon Health Institute

New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…

48 minutes ago

Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound

Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…

49 minutes ago

CelLBxHealth PLC Announces Board Changes

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…

4 hours ago

Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms

Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…

5 hours ago

Pre-JPM Investor Pulse Signals 2026 Capital Rotation Toward “AI That Ships,” Admin Cost Takeout, and Differentiated Metabolic Assets With Special-Situations Capital Back in Scope

Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…

19 hours ago